A Move That Will Spark This Sector's Rally in 2024

One sector has taken a beating the past two years. But that could all change starting next year... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] This essay was originally published in DailyWealth Trader, a daily trading advisory, and has been adapted. To learn more about this service, [click here](. --------------------------------------------------------------- A Move That Will Spark This Sector's Rally in 2024 By Chris Igou, editor, DailyWealth Trader --------------------------------------------------------------- The feds are getting in the way of one sector's rise... Their actions have been hurting these companies for years. And with their thumb pressing down on a key figure, the feds have a big impact on what comes next in this sector. I'm not talking about police oversight or the FBI knocking on doors. I mean the other Feds... the ones that determine the world's most important figure in finance... They monitor how easily and cheaply companies can grow their business. For almost two years, they've made it more difficult across the board. But that's all likely to change starting next year. And as I'll explain today, one of the sectors that has been hurt the most in the past two years will likely soar. --------------------------------------------------------------- Recommended Links: [A Severe Financial Crisis Is Underway]( It doesn't matter whether you have money in the markets right now or are waiting on the sidelines. The short period we're about to enter could have the power to make – or destroy – fortunes. And what you do in the coming days could determine your wealth for the next decade. [Click here to learn more](. --------------------------------------------------------------- [Gold Is Headed Above $3,000 per Ounce (Here's How to Play It)]( With so many strange events happening across the economy (the longest bear market for bonds since the Civil War... unprecedented bank closures... and soaring prices), it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – WITHOUT ever touching an ETF, mining stock, or even bullion. [Get the full details here](. --------------------------------------------------------------- The cost to borrow skyrocketed in 2022 and 2023. The Federal Reserve drove its benchmark interest rate up from near zero to around 5.5% today. Now, though, the world expects that rate to fall... A recent Bankrate survey shows that 94% of economists expect rate cuts in 2024. Only 6% believe we won't see a rate cut until 2025 or later. It goes beyond that survey, too. Famed investor Bill Ackman thinks we could see a rate cut in the first quarter of 2024. And then there are headlines like this one from Fox Business... We can't be sure exactly when the first rate cut will be. But the consensus is that it will fall next year. To prepare, we can look at the markets to find what will soar when rates are low again – that is, when cheap debt returns. And some of the biggest benefactors will be debt-heavy businesses... You see, when rates are high, debt-heavy businesses suffer. Their future growth prospects dwindle. And they go back to being slow growers as a result. The opposite is true when the Fed cuts rates. Capital-heavy businesses get easier access to the cash they need to grow. And the gains that follow tend to be rapid. Biotechnology companies are a great example. They require a lot of capital for research, drug development, and drug trials. That can mean large debt loads. And at higher rates, that debt burden can hurt a company's bottom line. It eats into the cash available to invest in the business or pay dividends to investors. This explains why biotech stocks suffered the past two years. The iShares Biotechnology Fund (IBB) is down 30% since peaking in 2021. Check it out... Like I mentioned earlier, the federal-funds rate has skyrocketed from near zero at the start of 2022 to 5.5% today. And biotech stocks have taken a beating. But the opposite tends to happen once rates fall back to low levels. Let's look at a longer-term chart to see how this has previously played out. There have been three big biotech booms since 2000. All of them took place after rates fell and the cost to borrow became cheap... A similar pattern happens each time. Biotech stocks fall during the initial rate cut. Then, they go on multiyear booms with incredible gains on the table. The first example starts in 2002... The sector rose 101% from July 2002 into April 2004. That's a triple-digit gain in less than two years. That rally looks like child's play compared with what happened in the early 2010s. Interest rates were near zero for six years straight. And IBB rose 583% from its March 2009 low into July 2015. The latest boom from 2020 through 2021 wasn't as big. But it was good for a near triple-digit gain in a year and a half, as biotech stocks rose 87% to their August 2021 peak. We aren't there yet in the current environment. The Feds are holding interest rates steady for now. But that will likely change in 2024... potentially as soon as the first quarter. And when rates start to drop dramatically, that's when you should consider owning biotech stocks. Good investing, Chris Igou Further Reading "The next biotech bull market appears to be setting up now," Brett Eversole writes. Biotech stocks have taken a beating this year. But once this trend reverses and investor sentiment is back in favor of tech, the sector could experience a massive surge higher... [Read more here](. If you're thinking about buying biotech stocks, do your homework first. It's wise to look for companies that are investing for the future and building value that can last. Follow these key clues to position yourself for success in this sector... [Learn more here](. --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You're receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2023 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.